Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures

尿素循环失调产生具有临床意义的基因组和生化特征

阅读:4
作者:Joo Sang Lee ,Lital Adler ,Hiren Karathia ,Narin Carmel ,Shiran Rabinovich ,Noam Auslander ,Rom Keshet ,Noa Stettner ,Alon Silberman ,Lilach Agemy ,Daniel Helbling ,Raya Eilam ,Qin Sun ,Alexander Brandis ,Sergey Malitsky ,Maxim Itkin ,Hila Weiss ,Sivan Pinto ,Shelly Kalaora ,Ronen Levy ,Eilon Barnea ,Arie Admon ,David Dimmock ,Noam Stern-Ginossar ,Avigdor Scherz ,Sandesh C S Nagamani ,Miguel Unda ,David M Wilson 3rd ,Ronit Elhasid ,Arkaitz Carracedo ,Yardena Samuels ,Sridhar Hannenhalli ,Eytan Ruppin ,Ayelet Erez

Abstract

The urea cycle (UC) is the main pathway by which mammals dispose of waste nitrogen. We find that specific alterations in the expression of most UC enzymes occur in many tumors, leading to a general metabolic hallmark termed "UC dysregulation" (UCD). UCD elicits nitrogen diversion toward carbamoyl-phosphate synthetase2, aspartate transcarbamylase, and dihydrooratase (CAD) activation and enhances pyrimidine synthesis, resulting in detectable changes in nitrogen metabolites in both patient tumors and their bio-fluids. The accompanying excess of pyrimidine versus purine nucleotides results in a genomic signature consisting of transversion mutations at the DNA, RNA, and protein levels. This mutational bias is associated with increased numbers of hydrophobic tumor antigens and a better response to immune checkpoint inhibitors independent of mutational load. Taken together, our findings demonstrate that UCD is a common feature of tumors that profoundly affects carcinogenesis, mutagenesis, and immunotherapy response.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。